|
Immune Response (OTCBB: IMNR) Secures Partners for MS Clinical Trials |
|
|
|
Immune Response Corporation recently announced on that it has entered
into an agreement with Accelsiors CRO & Consultancy Services, a
clinical research organization with extensive experience in conducting
multiple sclerosis (MS) trials, to oversee the 200-patient Phase II
trial of NeuroVax, an investigational T-cell receptor peptide vaccine
for the treatment of MS. Immune went on further to announce that in
November they will hold a clinical trial meeting in Budapest, Hungary
to discuss plans for a multi-center trial. This trial will also be a
double-blind placebo control test to further investigate the viability
of NeuroVax as a treatment for MS.
The trial will enroll around two hundred patients with
relapsing-remitting MS and it will examine the effectiveness of
NeuroVax as compared to the placebo. The primary objective of the study
is to compare the cumulative number of new gadolinium enhancing
lesions, a key marker of MS disease activity, using MRI scans at 24,
32, 40, and 48 weeks. Secondary objectives rang from remission
calculations to safety concerns surrounding any new, experimental drug.
In addition to partnering with the clinical research organization,
Immune Response has also partnered with NeuroRx Research, a company
with special expertise in advanced MRI acquisition and analysis
techniques, to oversee professional management of all MRI-related study
activities.
The Immune Response Corporation is an immuno-
pharmaceutical company focused on developing products to treat
autoimmune and infectious diseases. The Company's lead immune-based
therapeutic product candidates are NeuroVax(TM) for the treatment of MS
and IR103 for the treatment of HIV infection. Both of these therapies
are in Phase II clinical development and are designed to stimulate
disease pathogen-specific immune responses aimed at slowing or halting
the rate of disease progression. Both drugs currently show promise in
their effectiveness, and if successful, should drive the company's
stock higher. |
